Compared with high-risk MDS-MSC, low-risk MDS-MSC had little effect on CD80, CD83 and CD86 expression, indicating that the effect of low-risk MDS-MSC on DCs maturation was weaker than that of high-risk MDS-MSC (Figure 1C–D). The gene discussed is CD86; the disease is myelodysplastic syndrome.